The oversubscribed funding was led by strategic investors from within the spine industry along with prominent and continuing investment by the Genesis Innovation Group’s cultivate(MD) Seed II Fund.
The oversubscribed funding was led by strategic investors from within the spine industry along with prominent and continuing investment by the Genesis Innovation Group’s cultivate(MD) Seed II Fund.